The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 29, 2008

Filed:

Jun. 21, 2005
Applicants:

Mindy Tsai, Palo Alto, CA (US);

See-ying Tam, Palo Alto, CA (US);

Stephen J. Galli, Portola Valley, CA (US);

Inventors:

Mindy Tsai, Palo Alto, CA (US);

See-Ying Tam, Palo Alto, CA (US);

Stephen J. Galli, Portola Valley, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); A01K 67/033 (2006.01); G01N 33/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

Non-human transgenic animal models and cells derived therefrom are provided for RabGEF1 function. RabGEF1 is a negative regulator of FcεRI-dependent mast cell activation and T cell activation via the T cell receptor and a lack of RabGEF1 results in the development of skin inflammation in vivo. The mast cells derived from such animals exhibit enhanced Ras-mediated signaling and functional responses when activated through high affinity IgE receptors. These cells show significant potentiation of IgE and antigen-dependent secretion of 3 classes of mast cell mediators, providing a useful source of mast cells for screening assays. The animals and cells derived therefrom are also useful for screening biologically active agents that may modulate RabGEF1 function, including therapeutic agents for the treatment of skin disorders, such as eczema, psoriasis, and the like, or for the treatment of other mast cell-associated disorders, including allergic disorders, such as asthma and hay fever, and certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Inhibiting RabGEF1 function may be useful in those conditions in which it is desirable to enhance T cell and/or mast cell function, such as in AIDS or other immune deficiency disorders.


Find Patent Forward Citations

Loading…